A study to compare different combinations of Mirabegron (25 or 50 mg) and and antimuscarinic in the treatment of patients with overactive bladder

Trial Profile

A study to compare different combinations of Mirabegron (25 or 50 mg) and and antimuscarinic in the treatment of patients with overactive bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Mirabegron (Primary) ; Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2016 New trial record
    • 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top